Summary of findings for the main comparison. Glucocorticoid versus placebo: summary of findings.

Glucocorticoid versus placebo for acute viral bronchiolitis in infants and young children
Patient or population: infants and young children with acute viral bronchiolitis Settings: outpatients and inpatients Intervention: glucocorticoid versus placebo
Outcomes	Illustrative comparative risks* (95% CI)		Steroid versus placebo	No of participants (studies)	Quality of the evidence (GRADE)
	Assumed risk1	Corresponding risk
	Placebo	Steroid
Admissions (outpatients) Follow‐up: day 1	Medium risk population		RR 0.92 (0.78 to 1.08)	1762 (8)	high
	162 per 1000	149 per 1000 (126 to 175)
Admissions (outpatients) Follow‐up: day 7	Medium risk population		RR 0.86 (0.7 to 1.06)	1530 (5)	moderate
	250 per 1000	215 per 1000 (175 to 265)
Length of stay (inpatients) days	The mean length of stay ranged across control groups from 0.8 to 6.6 days	The mean length of stay in the intervention groups was 0.18 lower (0.39 lower to 0.04 higher)		633 (8)	high
*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI) CI: confidence interval RR: risk ratio
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.

¹Assumed risk for admissions was based on the median control group risks across the studies included in the meta‐analysis (medium risk).